Term ends Jun 8, 2032 · High confidence
20-year base term ends Jun 8, 2032
Jun 8, 2012
Jun 8, 2032
Feb 1, 2022
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 8, 2012, when application PCT/US2012/041663, the earliest non-provisional in its chain, was filed (this one was filed Feb 13, 2020) | Jun 8, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,137,086, US 10,137,087, US 10,786,455, US 11,497,716) | resolves to Jun 8, 2032, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 8, 2032 | High confidence |
This family
| Application PCT/US2012/041663 | PCT application no patent term | no patent term |
| US 9,717,690 | In force Feb 2033 | Feb 2033 |
| Application 15/651,832 | Abandoned not computed | not computed |
| US 10,507,183 | In force Jun 2032 | Jun 2032 |
| US 10,702,478 | In force Jun 2032 | Jun 2032 |
| US 11,234,936 | this patent Jun 2032 | Jun 2032 |
| US 12,102,720 | In force Oct 2032 | Oct 2032 |
| Application 18/815,955 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 19, 2021 Reel 55339, frame 918 | Guild, Braydon Charles; Heartlein, Michael; Derosa, Frank; Zhang, Jerry Chi | Shire Human Genetic Therapies, Inc. | Assignment of Assignor's Interest |
| Feb 19, 2021 Reel 55344, frame 512 | Shire Human Genetic Therapies, Inc. | Rana Therapeutics, Inc. | Assignment of Assignor's Interest |
| Feb 19, 2021 Reel 56443, frame 707 | Rana Therapeutics, Inc. | Translate Bio, Inc. | Change of Name |
| Mar 11, 2021 Reel 55571, frame 260 | Rana Therapeutics, Inc. | Translate Bio, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 10,137,086, US 10,137,087, US 10,786,455, US 11,497,716, ends no earlier than this term, so it caps nothing.